Published • loading... • Updated
Metagenomi Details Hemophilia A Gene-Insertion Plans at Chardan Conference
Summary by thecerbatgem.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Metagenomi Details Hemophilia A Gene-Insertion Plans at Chardan Conference
Executives from Epicrispr and Metagenomi (NASDAQ:MGX) outlined next-generation gene regulation and gene-editing approaches at a Chardan discussion focused on platforms beyond conventional CRISPR gene cutting. Chardan Senior Biotech Analyst Keay Nakae said traditional CRISPR approaches use guide RNA to direct an enzyme to a DNA location, where it creates a double-stranded break. The panel examined […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
